Frontage Receives 2019 CRO Leadership Awards
7.1.2019

Frontage Receives 2019 CRO Leadership Awards

Read Full Story
Filter By:
News Frontage Holdings Corporation Celebrates a Successful Initial Public Offering on the HKEx
6.3.2019

Frontage Holdings Corporation Celebrates a Successful Initial Public Offering on the HKEx

Frontage Holdings Corporation, the parent company of Frontage Laboratories, Inc., a fast-growing contract research organization, specializing in R&D product development services, with operations in both the United States and China, announced on May 30th that the Company's Shares have initiated trading on the Main Board of The Stock Exchange of Hong Kong
Read Full Story
News Frontage Appoints Sridhar Krishnan as Senior Vice President of Global Operations!
5.9.2019

Frontage Appoints Sridhar Krishnan as Senior Vice President of Global Operations!

As Senior Vice President of Global Operations, Sridhar will be responsible for integrating business units and provide operational excellence leadership across the Frontage organization.
Read Full Story
News Dr. Song Li Awarded Entrepreneur Of The Year®
6.19.2018

Dr. Song Li Awarded Entrepreneur Of The Year®

Dr. Song Li, Founder and CEO of Frontage Laboratories, Inc., has been awarded the Entrepreneur Of The Year®Award for 2018. 
Read Full Story
News Dr. Song Li Wins Healthcare CEO Enterprise Award
5.16.2018

Dr. Song Li Wins Healthcare CEO Enterprise Award

Dr. Song Li, Founder and CEO of Frontage Laboratories, Inc., has been awarded the Healthcare CEO of the Year Enterprise Award for 2018.
Read Full Story
News Frontage Appoints Hugh Davis as Chief Business Officer
5.3.2018

Frontage Appoints Hugh Davis as Chief Business Officer

Frontage Laboratories, Inc., is pleased to announce the appointment of Dr. Hugh Davis as Chief Business Officer (CBO), in charge of Business Development, Sales, Marketing and Strategic Partnerships.
Read Full Story
News Frontage acquires Concord Biosciences
4.5.2018

Frontage acquires Concord Biosciences

Frontage Laboratories, Inc., a global CRO with headquarters in Exton, Pennsylvania, announces the acquisition of Concord Biosciences, formerly known as Ricerca Biosciences, LLC, a preclinical CRO located near Cleveland, Ohio. Founded in 1986, Concord Bio supports the pharmaceutical, agricultural, chemical, and animal health industries with Drug Safety, Metabolism, Bioanalytical, Residue, and Environmental Fate studies.

Dr. Song Li, Founder and CEO of Frontage Laboratories, said, “We have committed to build a global CRO company with integrated services. The acquisition of Concord Biosciences is a significant step toward reaching our goal. The addition of Concord Bio to the Frontage family will enable us to provide pharmaceutical product development services from lead selection to IND-enabling studies to commercialization. Additionally, the agrochemical expertise of Concord Bio will position Frontage as a major CRO in the agricultural products industry.”.

About Frontage:
Frontage Laboratories, Inc., a full-service early-stage CRO with locations in the USA and China, has been assisting global biopharmaceutical organizations in their drug development efforts since 2001. Spanning from discovery through late-stage development, its full service offerings include DMPK, bioanalysis, analytical testing, product development and full biometrics support. Frontage also provides turnkey product development services to generic, innovator and consumer health pharmaceutical companies to support IND, NDA, ANDA, and 505(b)(2) submissions. Frontage has successfully enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development to commercial launch in global markets. For more information, visit https://www.frontagelab.com/

About Concord Biosciences:
Founded in 1986, Concord is a contract research organization that supports the pharmaceutical, agricultural, and animal health industries. Our comprehensive, integrated suite of services help our clients meet their regulatory requirements and internal development goals. Located on a 20-acre campus in Concord, Ohio, our expansive facilities allow for Concord to operate on the scale of a large CRO, while offering the nimbleness of a small CRO. Concord is relentless in its pursuit of client service and adding value to client situations through accelerating timelines and providing expert collaboration. For more information, visit http://www.concordbio.com/



Read Full Story